You are viewing the site in preview mode
Skip to main content
| |
All
|
China
|
South Asia
|
East Asia
|
North Africa
|
Middle East
|
Latin America
|
Russia
|
|---|
|
Patients with macrovascular complications
| | | | | | | | |
|
RAS blocker, n (%)
|
13,910 (78.1)
|
1,303 (55.6)
|
3,771 (76.3)
|
1,992 (74.2)
|
778 (79.5)
|
3,719 (86.6)
|
285 (85.1)
|
2,062 (92.6)
|
|
Aspirin, n (%)
|
13,995 (78.6)
|
1,644 (70.2)
|
3,784 (76.6)
|
1,866 (69.5)
|
801 (81.8)
|
3,973 (92.5)
|
252 (75.2)
|
1,675 (75.2)
|
|
Statins, n (%)
|
11,958 (67.2)
|
1,139 (48.6)
|
3,057 (61.9)
|
1,846 (68.8)
|
715 (73.0)
|
3,710 (86.4)
|
189 (56.4)
|
1,302 (58.5)
|
|
Patients with microvascular complications
| | | | | | | | |
|
RAS blocker, n (%)
|
21,884 (62.6)
|
2,268 (41.5)
|
4,792 (58.5)
|
3,465 (61.7)
|
1,557 (65.0)
|
6,907 (70.1)
|
499 (69.8)
|
2,396 (87.3)
|
|
Aspirin, n (%)
|
22,207 (63.5)
|
2,704 (49.5)
|
4,958 (60.6)
|
2,698 (48.0)
|
1,598 (66.7)
|
7,922 (80.5)
|
427 (59.7)
|
1,900 (69.2)
|
|
Statins, n (%)
|
19,709 (56.4)
|
1,856 (33.9)
|
4,325 (52.8)
|
3,133 (55.8)
|
1,288 (53.7)
|
7,323 (74.4)
|
312 (43.6)
|
1,472 (53.6)
|
- Note: due to the observational nature of this study, not all baseline data were recorded.
- RAS = renin-angiotensin system.
